Our group was the first to evaluate the feasibility of large-scale screening for EGFR mutations in patients with advanced NSCLC and analyze the association between the mutations and the outcome of erlotinib treatment.8 The gene discussed is EGFR; the disease is non-small cell lung carcinoma.